Dr. Steven J. Chmura is an Associate Professor in the Department of Radiation and Cellular Oncology and Director of Clinical and Translational Research at The University of Chicago.
Steven J. Chmura MD, PhD is the director of Clinical and Translational Research for Radiation Oncology at the University of Chicago for over a decade. He has been actively involved in both the clinical implementation of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) and related translational and clinical research, as well as the integration of SRS and SBRT into other systemic therapies. His clinical interests include breast cancer, limited metastatic disease, immunotherapy, and technologic improvements in the delivery of radiotherapy. Dr. Chmura is a leader in the NCI cooperative groups. His work has led to the first international oligmetastatic trials through NRG Oncology examining the safety of treating lung and breast cancer patients as a Phase II/III trial examining potential improvements to progression-free survival and overall survival. Dr. Chmura's work in radio-immunology has also translated into multiple investigator-sponsored trials along with the now accruing NCI-sponsored (A091605) trial randomizing the role of SBRT combined with pembrolizumab in advanced Merkel cell carcinoma; such integration of ablative radiotherapy and immunotherapy along with advancing the search for biomarkers is currently Dr. Chmura's focus.
University of Chicago
Chicago
- Radiation Oncology Board Certification
2005
University of Chicago
Chicago
PhD - Pathology
1999
University of Chicago
Chicago
MD - Medicine
1999
University of Illinois
Urbana
BS - Biology and Psychology
1992
Radiation dose, schedule and novel systemic targets for radio-immunotherapy combinations.
Radiation dose, schedule and novel systemic targets for radio-immunotherapy combinations. J Natl Cancer Inst. 2023 Jun 22.
PMID: 37348864
Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?
Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy? J Natl Cancer Inst. 2023 06 08; 115(6):605-607.
PMID: 35094086
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy.
YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
PMID: 37236197
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
PMID: 37183819
Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases.
Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases. JAMA Netw Open. 2023 04 03; 6(4):e2310117.
PMID: 37099292
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade.
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 Nov 28.
PMID: 36443406
Flipping the Null: Lessons From Breast Cancer and Recalibrating Expectations in Oligometastases.
Flipping the Null: Lessons From Breast Cancer and Recalibrating Expectations in Oligometastases. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):840-842.
PMID: 36395805
Reply to J. Widder.
Reply to J. Widder. J Clin Oncol. 2023 02 01; 41(4):939-940.
PMID: 36288507
Prognostic Model for Intracranial Progression after Stereotactic Radiosurgery: A Multicenter Validation Study.
Prognostic Model for Intracranial Progression after Stereotactic Radiosurgery: A Multicenter Validation Study. Cancers (Basel). 2022 Oct 22; 14(21).
PMID: 36358606
Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?
Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It? Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):561-570.
PMID: 36244387